Low Dose REN001
REN001-102
Phase 1 small_molecule completed
Quick answer
Low Dose REN001 for Fatty Acid Oxidation Disorders is a Phase 1 program (small_molecule) at OnKure Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- OnKure Therapeutics
- Indication
- Fatty Acid Oxidation Disorders
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed